# Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy

> **NCT07355868** · EARLY_PHASE1 · RECRUITING · sponsor: **Regend Therapeutics** · enrollment: 12 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **BIOLOGICAL:** REGEND007

## Key facts

- **NCT ID:** NCT07355868
- **Lead sponsor:** Regend Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-19
- **Primary completion:** 2026-10-15
- **Final completion:** 2026-12-15
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07355868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07355868, "Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07355868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*